SingleCognitive & Sleep

DSIP 5mg

Endogenous nonapeptide examined in experimental protocols for slow-wave sleep architecture, circadian rhythm modulation, and stress response.

Mechanism

DSIP acts as an endogenous neuromodulator that promotes delta-wave slow-wave sleep rhythms and tempers HPA axis activity via putative interactions with central GABAergic and opioid transmission networks.

Dosing

Published research protocols document a daily starting level of 100 mcg administered subcutaneously, titrated upward gradually based on study design.

Reconstitution

Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water produces an approximate concentration of 1.67 mg/mL (16.7 mcg per U-100 unit).

Storage

Store the dry lyophilized compound at -20 °C, and preserve the reconstituted solution between 2 °C and 8 °C protected from light, avoiding repeated freeze-thaw cycles.

Mix & measure DSIP 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure DSIP 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.67mg/mL

Draw volume0.060mL

On the syringe6.00units

Total doses in vial: 50.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Week 1	100 mcg (1× daily)	6 units (0.06 mL)
Week 2	150 mcg (1× daily)	9 units (0.09 mL)
Week 3	200 mcg (1× daily)	12 units (0.12 mL)
Weeks 4–8	250–300 mcg (1× daily)	15–18 units (0.15–0.18 mL)

Reconstitution Steps

1
Aseptically clean the rubber septums of both the DSIP and bacteriostatic water vials using fresh sterile alcohol pads.
2
Draw exactly 3.0 mL of bacteriostatic water into a sterile syringe.
3
Introduce the needle into the DSIP vial and discharge the diluent gently along the interior glass wall to minimize turbulent agitation and foaming.
4
Gently swirl and invert the vial until the lyophilized cake is fully dissolved without vigorous shaking.
5
Affix a label noting reconstitution date and working concentration, then store immediately at 2–8 °C.

Supplies Needed

Peptide Vial

Contains 5 mg of lyophilized DSIP research material

Insulin Syringes (U-100)

Used for precise measurement and subcutaneous delivery of micro-volume allocations

Bacteriostatic Water

Provides 3.0 mL of preserved sterile diluent required for reconstitution

Alcohol Swabs

Used to maintain sterile technique on vial stoppers and injection sites

Why researchers study it

Slow-wave (delta) sleep induction and architecture preservation

Hypothalamic-pituitary-adrenal (HPA) axis stress modulation

Central analgesic mechanisms and pain perception pathways

Preclinical neuroprotection and mitigation of oxidative strain

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Delta Sleep-Inducing Peptide (DSIP) is an endogenous nonapeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that was originally isolated from the cerebral venous blood of rabbits undergoing low-frequency electrical stimulation. Historically investigated for its regulatory influence on sleep macro-architecture, experimental interest centers on its capacity to selectively facilitate delta EEG rhythms without suppressing REM phases. Unlike standard sedative-hypnotics, it does not induce immediate narcosis but rather appears to modulate physiologic restorative patterns. Beyond basic sleep physiology, laboratory literature describes broader adaptogenic and neuromodulatory properties. DSIP has been evaluated for its potential interactions with the central neuroendocrine axes, specifically attenuating stress responses driven by the hypothalamic-pituitary-adrenal (HPA) cascade. Researchers have highlighted its ability to preserve cellular integrity during biochemical or oxidative strain in preclinical neural models. DSIP remains an unregulated, investigational chemical strictly restricted to preclinical research settings. Because human trials remain dated and limited, standardized clinical parameters do not exist. Experimental laboratory inquiries are aimed at dissecting its elusive secondary signaling pathways, receptor affinity, and neurochemical effects across animal models.

References

1.Schoenenberger GA, Monnier M, Proc Natl Acad Sci USA, 1977 — Characterization of a delta-electroencephalogram (-sleep)-inducing peptide isolated from rabbit brain
2.Editorial Review, European Journal of Anaesthesiology, 2001 — Delta sleep-inducing peptide: editorial review of proposed mechanisms and clinical context
3.Schneider-Helmert D, Schoenenberger GA, Neuropsychobiology, 1983 — Effects of DSIP in man: multifunctional psychophysiological properties
4.Sudakov KV et al., Ann N Y Acad Sci, 2004 — Delta-sleep-inducing peptide sequelae: stress-protective effect
5.Schneider-Helmert D, Int J Clin Pharmacol Ther Toxicol, 1981 — Acute and delayed effects of DSIP on human sleep behavior
6.Graf MV, Kastin AJ, Neurosci Biobehav Rev, 1984 — Delta-sleep-inducing peptide (DSIP): a review
7.Wang W, Int J Pharm, 2000 — Lyophilization and development of solid protein pharmaceuticals (stability and storage)
8.Manning MC et al., Pharm Res, 2010 — Stability of protein pharmaceuticals: an update
9.Yehuda S, Carasso RL, Int J Neurosci, 1988 — DSIP: proposed brain mechanisms and function
10.Khvatova EM et al., Biull Eksp Biol Med, 2003 — Delta sleep-inducing peptide: effect on oxidative stress in brain